The updated UK guidelines for HER2 testing were published in December 2022 [1] and focused on several areas, including the concept of HER2-low breast cancer defined as IHC 1+ or 2+ without gene amplification on FISH. This evidence concerns the gene ERBB2 and breast cancer.